Treatment-induced blood pressure reduction and the risk of myocardial infarction

M H Alderman1, W L Ooi, S Madhavan

  • 1Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, NY 10461.

JAMA
|August 18, 1989
PubMed

Insights

Achieving a moderate reduction in diastolic blood pressure (BP) may lower the risk of myocardial infarction in mild to moderate hypertensives. Both large and small BP drops were linked to increased heart attack risk compared to moderate declines.

Area of Science:

  • Cardiology
  • Hypertension Management

Background:

  • Mild to moderate hypertension affects a significant population, necessitating effective treatment strategies.
  • The relationship between the degree of blood pressure reduction and cardiovascular outcomes like myocardial infarction requires further elucidation.

Purpose of the Study:

  • To investigate the association between the extent of treatment-induced blood pressure reduction and the incidence of myocardial infarction in previously untreated individuals with mild to moderate hypertension.

Main Methods:

  • A cohort of 1765 untreated patients with mild to moderate hypertension was reviewed.
  • Diastolic blood pressure (BP) reduction was categorized into small (≤6 mm Hg), moderate (7–17 mm Hg), and large (≥18 mm Hg) changes.
  • Cox regression analysis was employed to assess the relationship between BP reduction categories and myocardial infarction events.

Main Results:

  • Over an average follow-up of 4.2 years, 39 myocardial infarctions occurred.
  • Both large and small reductions in diastolic BP were associated with a higher incidence of myocardial infarction compared to a moderate decline.
  • Age and sex were identified as independent risk factors for myocardial infarction, while other factors like BMI and cholesterol were not significant.

Conclusions:

  • A moderate reduction in diastolic blood pressure may be an optimal treatment goal for patients with mild to moderate hypertension to minimize myocardial infarction risk.
  • The study suggests a non-linear relationship between diastolic BP reduction and cardiovascular events.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...